摘要
近年来急性肾损伤(AKI)在临床的发病率有增高趋势,且死亡率高,预后差。改善AKI预后的关键是早期诊断、早期干预。传统的诊断指标血清肌酐和尿素不能在早期反映肾小球滤过率的下降,且受到的影响因素多。近年来发现的一些新型的生物学标志物如中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、白介素-18(IL-18)、肾损伤分子-1(KIM-1)、钠氢交换子-3(NHE-3)、肝脏型尿脂肪酸结合蛋白(L-FABP)、尿富半胱氨酸蛋白61(cyr 61)、尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)、尿胎球蛋白A(fetuin-A)等能在早期反映肾功能的变化,具有临床应用前景。现就上述AKI生物标志物的研究进展做一综述。
In recent years, the clinical incidence of acute kidney injury （AKI） is increasing, with high mortality and poor prognosis. The key to improve the prognosis of AKI is early diagnosis and early intervention. Traditional markers of AKI, blood urea nitrogen and serum creatinine, cannot early reflect the decrease of glomerular filtration rate （GFR）, and can be influenced by a variety of factors not related to GFR changes. In recent years, a number of new biomarkers of AKI have been identified with clinical application prospects, which can reflect the early changes of the renal function, including neutrophil gelatinase-associated lipocalin （NGAL）, interleukin-18 （IL-18）, kidney injury molecule-1 （KIM-1）, sodium hydrogen exchanger-3, urinary liver-type fatty acid binding protein （L-FABP）, urinary cysteine-rich protein 61 （cyr 61）, urinary N-acetyl-β-D-glucosaminidase （NAG）, and urine fetuin A （fetuin-A）. This paper has reviewed the research progress of these biomarkers of AKI.
出处
《中华肾病研究电子杂志》
2013年第3期25-28,共4页
Chinese Journal of Kidney Disease Investigation（Electronic Edition）
